|
|
|
| The Efficacy of Levocarnitine Combined with Trimetazidine in the Treatment of Dilated Cardiomyopathy and its Impact on Patients' Cardiac Function |
| WEN Yaxiao, YANG Lihui, YANG Zhige |
| Nanyang First People's Hospital,Nanyang Henan 473000 |
|
|
|
|
Abstract 【Objective】To investigate the clinical efficacy of levocarnitine combined with trimetazidine in the treatment of dilated cardiomyopathy (DCM) and its impact on patients' cardiac function. 【Methods】A total of 102 DCM patients admitted to our hospital from January 2022 to February 2023 were selected and randomly divided into a control group (treated with trimetazidine in addition to conventional medication) and an observation group (treated with levocarnitine in addition to the control group) using a random number table method, with 51 patients in each group. Two groups of therapeutic effects were compared, including pre-and post-treatment cardiac function indicators such as cardiac index (CI), left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD), laboratory indicators such as periostin protein, transforming growth factor-β1 (TGF-β1), soluble growth stimulating gene 2 protein (sST2), cardiac troponin T (cTnT), creatine kinase isoenzyme (CK-MB), and myoglobin (Mb). 【Results】The total effective rate of the observation group was significantly higher than that of the control group, and the difference was statistically significant (P<0.05). After treatment, the CI and LVEF of both groups were higher than before treatment, and the observation group was higher than the control group; The LVEDD of both groups was lower than before treatment, and the observation group was lower than the control group, with a statistically significant difference (P<0.05). After treatment, cTnT, CK-MB, Mb, Periostin protein, TGF-β1, and sST2 in both groups were lower than before treatment, and the observation group was lower than the control group, with statistical significance (P<0.05). 【Conclusion】The combination of levocarnitine and trimetazidine is effective in treating DCM patients, improving their cardiac function and inhibiting ventricular remodeling.
|
|
Received: 31 August 2023
|
|
|
|
|
|
[1] 李莉,李翠文,张晓君,等.丹参酮ⅡA对扩张型心肌病患者合并恶病质后TLR4/JNK MAPK通路介导的TNF-α、IL-1和IL-6的抑制作用[J].中国老年学杂志,2023,43(10):2312.
[2] 杨曼曼,崔存英,张瑞,等.四维自动右心室定量分析技术评价扩张型心肌病患者右心室功能[J].中华超声影像学杂志,2023,32(6):485-492.
[3] 仲影,王冠,戴旭.心脏磁共振组织追踪技术评估扩张型心肌病左室应变及其诊断价值[J].磁共振成像,2021,12(7):6-11.
[4] 石庆元,黄菲菲,柳梅.曲美他嗪联合依折麦布通过调控miRNA对不稳定心绞痛患者PCI术后的临床疗效研究[J].临床和实验医学杂志,2022,21(14):1481-1485.
[5] 曹莉芳,赵闯.左卡尼汀对急性ST段抬高型心肌梗死经皮冠状动脉介入治疗术后的心肌保护作用[J].实用医学杂志,2022,38(8):942-945.
[6] MATHEW T, WILLIAMS L, NAVARATNAM G, et al. Diagnosis and assessment of dilated cardiomyopathy: a guideline protocol from the British Society of Echocardiography[J].Echo Res Pract,2017,4(2):G1-G13.
[7] 刘菲,杨文灿.沙库巴曲缬沙坦对扩张型心肌病心力衰竭患者心室重构和心脏功能的影响[J].中南医学科学杂志,2023,51(2):222-225.
[8] 李娅,杨姣,王立凤,等.RT-3DE容积-时间曲线评价扩张型心肌病病人左心室收缩期及舒张早期同步性的临床价值[J].中西医结合心脑血管病杂志,2023,21(1):121-124.
[9] 杨胜祥,雷玉华.左卡尼汀治疗儿童扩张型心肌病的疗效观察[J].临床与病理杂志,2019,39(6):1250-1254.
[10] 李瑾,刘江峰,符赵鑫.不同剂量曲美他嗪辅助治疗扩张型心肌病心力衰竭患者的疗效比较及血清相关细胞因子水平分析[J].岭南心血管病杂志,2023,29(2):180-183.
[11] 徐伟丽,刘勇先,朱华强.左卡尼汀联合曲美他嗪治疗老年扩张型心肌病患者的效果观察[J].广西医学,2021,43(21):2544-2548.
[12] 艾紫璇,孙玉,杨本强,等.基于MRI定量评估扩张型心肌病心功能及心肌应变的初步研究[J].医学影像学杂志,2022,32(9):1482-1487.
[13] 白杨,姜伟鹏,夏成蕴,等.血清NT-proBNP、HE4、β2-MG、sST2与扩张型心肌病患者心室重构的关系及对出院后短期预后的预测价值[J].现代生物医学进展,2022,22(17):3259-3263.
[14] 冯莉莉,王朝华,李贺,等.扩张型心肌病血清miR-210、β2-MG及TGF-β1水平的表达及其临床意义[J].现代生物医学进展,2022,22(4):688-692.
[15] 张玉霞,陈浩,张鸿,等.血浆Periostin蛋白、嗜铬粒蛋白A、可溶性Sema4D水平与扩张型心肌病慢性心力衰竭病人心功能分级和心室重构的相关性分析[J].安徽医药,2021,25(12):2514-2518. |
| [1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(6): 907-909. |
|
|
|
|
2024, Vol. 41 
